<DOC>
	<DOCNO>NCT01494415</DOCNO>
	<brief_summary>Nab-paclitaxel carboplatin show well treatment response compare cremophor-based paclitaxel carboplatin first-line therapy advance non-small cell lung cancer , especially squamous cell cancer . The regimen weekly nab-paclitaxel , carboplatin concurrent radiotherapy well tolerated phase I study . Given nab-paclitaxel , carboplatin concurrent radiotherapy patient local advance squamous cell lung cancer may promise result .</brief_summary>
	<brief_title>Concurrent Nab-P/Carboplatin Thoracic Radiotherapy Squamous Cell Lung Cancer</brief_title>
	<detailed_description>This study conduct explore efficacy toxicity concurrent chemoradiotherapy nab-paclitaxel , carboplatin thoracic radiotherapy unresectable local advance squamous cell lung cancer . Patients give nab-paclitaxel weekly dose 60mg/m2 , combination carboplatin ( AUC 2 ) weekly concurrent chemoradiotherapy . Thoracic radiation administer dose 66 Gy/33 fraction , 3 dimensional conformal intensity modulate radiation therapy allow . Two cycle consolidation therapy full dose nab-paclitaxel ( 260 mg/m2 day 1 ) carboplatin ( AUC 6 day 1 ) every 21 day deliver .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Scale . Previously untreated , histological document , inoperable stage IIIA IIIB squamous cell carcinoma lung , exclude pericardial , pleural effusion , contralateral hilar contralateral supraclavicular lymph node . Patients must measurable disease accord RECIST criterion , detectable tumor encompass radiation therapy field . Weight loss â‰¦ 5 % previous six month . Patient must adequate blood , liver , lung kidney function within requirement study . Female patient childbearing potential must test negative pregnancy time enrollment base serum pregnancy test . Male female patient must agree use reliable method birth control 3 month follow last dose study drug . Patients must sign studyspecific inform consent form prior study entry . Complete tumor resection , recurrent disease , patient eligible definitive surgery . Previous chemotherapy previous biologic response modifier current lung cancer . Patient previously thoracic radiation therapy . Prior concurrent malignancy except nonmelanomatous skin cancer unless diseasefree five year . Serious concomitant disorder would compromise safety patient , compromise patient 's ability complete study , discretion investigator . History significant neurological mental disorder , include seizure dementia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Squamous Cell Lung Cancer</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>chemotherapy</keyword>
</DOC>